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Background: D-3-aminoisobutyrate, an intermediary product of thymine, is converted to 2-methyl-3-oxopropanoate
using pyruvate as an amino acceptor by D-3-aminoisobutyrate-pyruvate aminotransferase (D-AIB AT; EC 2.6.1.40). A
large amount of D-AIB AT is distributed in the kidney and liver; however, small amounts are found in the brain.
Recently, D-AIB AT was reported to metabolize asymmetric dimethylarginine (ADMA) in vivo and was suggested
to be an important enzyme for nitric oxide metabolism because ADMA is a competitive inhibitor for nitric oxide
synthase. In this study, we examined the distribution of D-AIB AT in the rat brain further to understand its role.
We measured D-AIB AT mRNA and protein expression using quantitative RT-PCR and Western blotting, and
monitored its distribution using immunohistochemical staining.
Results: D-AIB AT was distributed throughout the brain, with high expression in the cortex and hippocampus.
Immunohistochemical staining revealed that D-AIB AT was highly expressed in the retrosplenial cortex and in
hippocampal neurons.
Conclusion: Our results suggest that D-AIB AT is distributed in the examined- just the regions and may play
an important role there.




ferase, EC 2.6.1.40, alanine: glyoxylate aminotransferase 2,
EC 2.6.1.44) is a unique aminotransferase that metabolizes
not L- but the D-isomer of 3-aminoisobutyrate (AIB) as
an amino donor and pyruvate as an amino acceptor to
generate 2-methyl-3-oxopropanoate and alanine. We, as
well as others, have previously purified and characterized
D-AIB AT in the rat liver [1,2], and its gene structure was
determined by Matsui-Lee et al. [3]. The condition result-
ing in high amounts of D-AIB excretion in the urine is
inherited in an autosomal recessive fashion [4], and indi-
viduals with this condition have been reported to lack
D-AIB AT activity [5]. D-AIB is an intermediate product* Correspondence: masao-a@m.ehime-u.ac.jp
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unless otherwise stated.of thymine, and D-AIB AT is the only enzyme that me-
tabolizes D-AIB (Kakimoto et al. [5,6]). High amounts
of D-AIB AT are distributed in the kidney and liver,
and small amounts have been identified in the brain.
However, no functional reason for D-AIB AT expression
in the central nervous system has been identified [7]. D-
AIB AT is also known to be a dimethylarginine-pyruvate
aminotransferase ([8], see Figure 1), which metabolizes
asymmetric dimethylarginine (ADMA) in vivo [9]. There-
fore, it appears that D-AIB AT is also an important en-
zyme for nitric oxide metabolism because ADMA is a
competitive inhibitor of the nitric oxide synthase (NOS)
enzyme family [10]. Endothelial (eNOS) and neuronal
(nNOS) play an obligatory role in the regulation of cere-
bral blood flow and cell viability, and in the protection of
nerve cells or fibers against pathogenic factors associated
with Alzheimer’s disease, Huntington’s disease, seizures,
and migraines [11]. Therefore, in this study, we monitored
the mRNA and protein expression of D-AIB AT in the rat
brain.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Metabolic pathway of D-AIB and ADMA. D-AIB AT can transaminate both D-AIB and ADMA with pyruvate as an amino acceptor.
Abbreviations: D-AIB AT; D-3-aminoisobutyrate aminotransferase, DDAH; dimethylarginine dimethylaminohydrolase, ADMA; asymmetric dimethylarginine,
DMGV; α-keto- δ-(NG,NG- dimethyl-guanidino) valeric acid. Protein names are underlined.
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Experimental animals
Male Wistar rats (CLEA Japan, Tokyo, Japan), 6–8 weeks
old, were housed in air-conditioned rooms (temperature,
22 ± 2°C) with a 12-h light–dark cycle. After rats were
anaesthetized with 30 ml of diethyl ether and decapitated,
the brain was removed and tissues used for examination
(frontal cortex, temporal cortex, cerebellum striatum, thal-
amus, hippocampus, midbrain, pons, and olfactory bulb)
were dissected. All experiments were approved by the
Ethics Review Committee for Animal Experimentation of
Ehime University.
RNA extraction and quantitation of D-AIB AT mRNA
expression
We examined ten rat (the ages of rat breakdown was
that 6 weeks old is six, 7 weeks old is two and 8 weeks
old is two) for RT-PCR. RNA was extracted from each
brain region isolated according to the RNeasy Lipid
Tissue Mini kit instructions (Qiagen, Valencia, CA, USA),
which included DNase treatment (Qiagen). Following as-
sessment of RNA quality and quantity with the NanoDrop
(NanoDrop Technologies, DE, USA), 1 μg of total RNA
was used for cDNA synthesis with random hexamers
using Moloney murine leukemia virus reverse transcript-
ase (Applied Biosystems, Austin, TX, USA). The expres-
sion of the D-AIB AT gene transcript was quantified byreal-time PCR with the TaqMan Gene Expression Assay
(Applied Biosystems). TaqMan primer-probe sets for D-
AIB AT (agxt2, Rn00582928_m1) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH, Ss03375435_u1),
used as an endogenous control, were purchased from
Applied Biosystems. Quantitative RT-PCR was performed
using the StepOnePlus System (Applied Biosystems).
Changes in D-AIB AT mRNA expression were calculated
after normalization with GAPDH expression. The cDNA
from an arbitrarily selected control rat were used as a
calibrator sample. The ΔΔCT method provided a relative
quantification ratio according to the calibrator, which
allowed statistical comparisons of gene expression among
samples. Values of fold changes in the sample versus the
frontal cortex samples represented averages from tripli-
cate measurements. Statistical calculations were carried
out using the SPSS Statistical Software Package 11.5
(SPSS, Tokyo, Japan). The mRNA expression differences
among brain tissues were analyzed by analysis of variance
with repeated measures followed by the Bonferroni post
hoc test. A P value less than 0.05 was considered statisti-
cally significant.
Western blotting
We examined four rat (all ages of rat is 6 weeks old)
for Western blotting. Brain tissue was homogenized in
lysis buffer containing 8.1 mM Na2HPO4, 2.68 mM
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and 2 mM 2-mercaptoethanol. Homogenates were cen-
trifuged at 16,000 g for 20 min at 4°C. The supernatant
was decanted into a new centrifuge tube. Protein con-
centrations for each brain region were determined
using the BCA Protein Assay Kit (Thermo Fisher Sci-
entific K.K., Yokohama, Japan). Protein samples (10 μg)
were suspended in Laemmli sample buffer, and sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophor-
esis was performed according to standard procedures.
Total lysates were separated on 1% SDS-polyacrylamide
gels, and were blotted onto polyvinylidene difluoride
membranes (Millipore, Bedford, MA, USA). After block-
ing with Blocking One (Nacalai Tesque, Kyoto, Japan),
the membranes were incubated with either anti-D-AIB
AT rabbit polyclonal primary antibody (specificity of
antibody show Additional files 1 and 2) generated using
the D-AIB-AT peptide ‘SPYTLGLTNVGIYKMEL’ (Japan
Bioserum, Hiroshima, Japan), or anti-GAPDH rabbit pri-
mary antibody (internal control; Abcam, Cambridge, UK)
diluted in 1% (v/v) Tween 20 at room temperature for
3 h. Membranes were treated with anti-rabbit goat
IgG horseradish peroxidase-linked Whole Antibody (GE
Healthcare, Buckinghamshire, UK) diluted in 1% (v/v)
Tween 20 at room temperature for 1 h. Visualization
using ChemiDoc MP (Bio Rad) was used for detection.
Image J (http://rsb.info.nih.gov/ij/index.html) was used
for Western blot analysis following digitization.
D-AIB AT immunohistochemistry
Wistar rat brains on postnatal day 7, 14, 28, and 56 were
used in this study. Animals were anesthetized by intra-
peritoneal injection of chloral hydrate (10 mg/kg) and
then perfused transcardially with physiological saline,
followed by 4% (w/v) paraformaldehyde in 100 mM
phosphate buffer (pH 7.4). Brains were removed and
post-fixed in the same solution for 12 h at 4°C and em-
bedded in paraffin wax. Frontal sections of rat brains
were cut at 5 μm, dewaxed in xylene, and rehydrated
with a graded series of ethanol solutions. Histochemistry
was performed using the anti-D-AIB AT antibody (this
antibody same as Western) in combination with the
avidin-biotin peroxidase complex (ABC) method using
the VECTASTAIN ABC kit (Vector Labs, Burlingame,
CA, USA). Endogenous peroxidase was blocked in meth-
anolic hydrogen peroxidase at 36°C for 30 min, and non-
specific protein binding was suppressed by incubation
with 1% (w/v) bovine serum albumin at 36°C for 30 min,
followed by rinsing with 0.02 M phosphate-buffered sa-
line (PBS; pH 7.4). Sections were incubated with the anti
D-AIB AT antibody at 4°C overnight. After rinsing with
PBS, the sections were further incubated with the VEC-
TASTAIN ABC reagent at room temperature for 30 min.
Finally, the sections were colorized with PBS containing0.006% (w/v) 3-3-diaminobenzidine tetrahydrochloride
and 0.003% (v/v) H2O2 at room temperature for 30 min,
and lightly counterstained with hematoxylin.
Results
D-AIB AT mRNA expression in the rat brain compared
with GAPDH mRNA expression, used as an internal
standard, is shown in Figure 2. D-AIB AT mRNA was
ubiquitously distributed in rat brain tissues. The mRNA
expression in the brain cortices, striatum and hippo-
campus were relatively high when compared with other
brain regions but there were no significant differences in
expression levels.
D-AIB AT protein levels were measured by Western
blotting (Figure 3). Protein levels of D-AIB AT in various
brain regions were compared with GAPDH. Expression
levels in parts of the midbrain (about five fold), hippo-
campus and olfactory bulb (about three fold) were high
when compared with frontal cortex.
Immunohistochemical studies revealed that hippocam-
pus is clearly stained with rabbit anti D-AIB AT antibody
(Figure 4b, compared with Figure 4a; pre-immune rabbit
serum). In the hippocampus, neurons in the CA1, CA3,
CA4, and dentate gyrus were strongly stained, particu-
larly the cytosolic region. The expression in the cerebral
cortex was weaker in the outer layer (Figure 4c) than
that in deep layers (Figure 4d). Neurons of the brainstem
were also strongly stained (Figure 4e). Compared with
other cortical regions, the retrosplenial cortex was
strongly stained (Figure 4f ). The rat which we examined
about each brain tissues is 8 weeks old. During develop-
ment (Figure 5; day 7 to 56 post partum), D-AIB AT
protein was highly expressed in the hippocampus, cortex,
and choroid plexus at all ages.
Discussion
To our knowledge, this is the first report to examine the
distribution of D-AIB AT in the rat brain. D-AIB AT
was distributed in examined- just the regions, with ex-
pression being greatest in deep layers of the cortex,
hippocampus, and brain stem. Immunohistochemistry
revealed that D-AIB AT expression was highest in the
retrosplenial cortex, hippocampus, brain stem, and chor-
oid plexus.
High amounts of D-AIB AT are distributed in the kid-
ney and liver [5], and small amounts are observed in
various regions of the brain [7]. Although the only known
role of D-AIB AT relates to the metabolism of D-AIB, its
precise function in the central nervous system remains
unclear. Recently, D-AIB AT was identified as an enzyme
that not only catalyzes the metabolism of D-AIB but also
catalyzes the degradation of ADMA, which is a competi-
tive inhibitor of NOS [12]. ADMA is present in the central


















































































Figure 2 Distribution of D-AIB AT mRNA in the rat brain. The mRNA expression in the frontal cortices was used as standard and represented
as 1.0 (n = 10). Bar shows the average ± S.E. Abbreviations: frontal, frontal cortex; temporal, temporal cortex.
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inhibits NO production in vitro [10] and actively degrades
ADMA in vivo [9]; however, ADMA is also degraded by
dimethylarginine dimethylaminohydrolase (DDAH) 1, a
member of the DDAH enzyme family [15]. We hypothesize






































Figure 3 Distribution of D-AIB AT protein in the rat brain with Weste
GAPDH are indicated in the upper figure. In the lower figure, density of D-
expression (n = 4).as an ADMA: pyruvate aminotransferase, an amino-
transferase that catalyzes ADMA with pyruvate to form
α-keto- δ-(NG,NG- dimethyl-guanidino) valeric acid and
alanine in vivo (Figure 1), resulting in a decrease to ADMA
brain levels, which helps NOS improve endothelial NO
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Figure 4 D-AIB AT immunohistochemistry in 8-week male rat brains. Figure 4a High magnification of hippocampal region with pre-immune
rabbit serum, Figure 4b; with rabbit anti D-AIB AT antibody are shown. Higher magnification of outer layer of cerebral cortex (Figure 4c), inner
layer of the cerebral cortex (Figure 4d), and brain stem (Figure 4e) are shown with anti D-AIB antibody. Figure 4f. Whole rat brains with coronal
sections (arrowheads indicates retrosplenial cortex) are shown with anti D-AIB antibody.







Figure 5 D-AIB AT immunohistochemistry in various brain regions from 7-, 14-, 28-, and 56-days-old male rats. The figures are: From left
to right; whole figure of hippocampus, CA1, CA3, DG (dentate gyrus), cortex, and choroid plexus, From top to bottom; 7-, 14-, 28-, and 56-days
postpartum male rat brains.
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in the examined- just the regions. Several studies sup-
port the idea that ADMA may be important regulator of
the NO system, where elevated ADMA concentrations
are associated with hypertension [16], congestive heart
failure [17], progression of chronic kidney disease [18]
and atherosclerosis [19]. D-AIB AT may be related to
the vulnerability for cerebro-vascular disease.
Our immunohistochemical studies revealed that D-
AIB AT is widely expressed in the retrosplenial cortex
and hippocampus. The rat retrosplenial cortex is similar
to Brodmann areas 29 and 30 in primates, which has
abundant reciprocal projections with the hippocampus
directly and indirectly [20]. Inactivation of the retrosple-
nial cortex is reported to impair active navigation in
dark testing conditions in a rat model with tetracaine
anesthetization of the retrosplenial cortex, suggesting that
this region is important for spatial memory [21]. Hippo-
campal atrophy is known to be one of the main symptoms
of Alzheimer’s disease (AD), and disruption of fronto-
hippocampal connections, not only directly but indirectly
through damage of the retrosplenial posterior cingulate
cortex, is observed in AD [22]. Metabolic decline in the
retrosplenial cortex is also reported in AD following posi-
tron emission tomography [23,24]. Pathological changes
in this region can also occur in schizophrenia, bipolardisorder, and post-traumatic stress disorder review [25].
Therefore the expression of D-AIB AT in brain lesions
formed following neurological disease progression.
Conclusion
In conclusion, D-AIB AT is widely distributed in the brain
and may work as an aminotransferase not only related to
degradation of D-AIB from thymine. Further studies will
be needed to clarify the role of D-AIB in the central ner-
vous system.
Additional files
Additional file 1: The ELISA data of rabbit anti D-AIB AT antibody.
The titer of the antibody was assessed by enzyme-linked immunosorbent
assay. ◆; pre-immune rabbit serum, ■; anti-D-AIB AT antibody.
Additional file 2: Western blot of rat brain tissues indicates the
comparison between rabbit pre-immune serum (left; × 1000) and
anti D-AIB antibody (right; × 1000).
Abbreviations
D-AIB: D-3-aminoisobutyrate; AT: Aminotransferase; ADMA: Asymmetric
dimethylarginine; RT-PCR: Real time-polymerase chain reaction; NOS: Nitric
oxide synthase; eNOS: Endothelial nitric oxide; nNOS: Neuronal nitric
oxide; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase;
EDTA: Ethylenediaminetetraacetic acid; SDS: Sodium dodecyl sulfate;
ABC: Avidin-biotin peroxidase complex; PBS: Phosphate-buffered saline;
DDAH: Dimethylarginine dimethylaminohydrolase; NO: Nitric oxide;
AD: Alzheimer’s disease.
Abe et al. BMC Neuroscience 2014, 15:53 Page 7 of 7
http://www.biomedcentral.com/1471-2202/15/53Competing interests
The authors declare that they have no competing interests.Authors’ contributions
MA, SO, YM, KY, TI, YY carried out the molecular genetic studies, participated
in the mRNA expression and Western blotting. SM participated in the
immunohistochemistry. MA have been involved in drafting the manuscript,
while RF, ST, SM revised it critically for important intellectual content. SU
supervised this study, participated in its design and coordination, and revised
the manuscript that led to the final approval of the current submission. All
authors read and approved the final manuscript.Acknowledgments
The authors wish to thank Ms. Mayumi Doi for her technical assistance. This
work was partially supported by Grants from the Ministry of Health, Labour
and Welfare of the Japanese Government and from the Japanese Ministry of
Education, Culture, Sports, Science and Technology.
Author details
1Department of Neuropsychiatry, Ehime University Graduate School of
Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan. 2Department of
Anatomy and Embryology, Neuroscience, Ehime University Graduate School
of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan. 3Department of
Neuropsychiatry, Faculty of Medical and Pharmaceutical Sciences, Kumamoto
University, 1-1-1, Honjo, Chuou-ku, Kumamoto, Kumamoto 860-8556, Japan.
Received: 10 September 2013 Accepted: 4 April 2014
Published: 27 April 2014References
1. Ueno S, Morino H, Sano A, Kakimoto Y: Purification and characterization of
D-3-aminoisobutyrate-pyruvate aminotransferase from rat liver. Biochim
Biophys Acta 1990, 1033:169–175.
2. Tamaki N, Kaneko M, Mizota C, Kikugawa M, Fujimoto S: Purification,
characterization and inhibition of D-3-aminoisobutyrate aminotransferase
from the rat liver. Eur J Biochem 1990, 189:39–45.
3. Matsui-Lee IS, Muragaki Y, Ideguchi T, Hase T, Tsuji M, Oschima A, Okuno E:
Molecular cloning and sequencing of a cDNA encoding alanine-glyoxylate
aminotransferase 2 from rat kidney. Biochem 1995, 117:856–862.
4. Yanai J, Kakimoto Y, Tsujio T, Sano I: Genetic study of beta-aminoisobutyric
acid excretion by Japanese. Am J Hum Genet 1969, 21:115–132.
5. Kakimoto Y, Taniguchi K, Sano I: D-β-aminoisobutyrate:pyruvate
aminotransferase in mammalian liver and excretion ob b
aminoisobutyrate in man. J Biol Chem 1969, 244:336–340.
6. Kakimoto Y, Armstrong MD: The preparation and isolation of D-(−)-beta-
aminoisobutyric acid. J Biol Chem 1961, 236:3283–3286.
7. Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R, Bar-Even A,
Horn-Saban S, Safran M, Domany E, Lancet D, Shmueli O: Genome-wide
midrange transcription profiles reveal expression level relationships in
human tissue specification. Bioinformatics 2005, 21(5):650–659.
8. Ogawa T, Kimoto M, Sasaoka K: Dimethylarginine:pyruvate aminotransferase
in rats. Purification, properties, and identity with alanine:glyoxylate
aminotransferase 2. J Biol Chem 1990, 265:20938–20945.
9. Martens-Lobenhoffer J, Rodionov RN, Drust A, Bode-Böger SM: Detection
and quantification of α-keto-δ-(N (G), N (G)-dimethylguanidino) valeric
acid: a metabolite of asymmetric dimethylarginine. Anal Biochem 2011,
419:234–240.
10. Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR: Human Alanine-
Glyoxylate Aminotransferase 2 Lowers Asymmetric Dimethylarginine and
Protects from Inhibition of Nitric Oxide Production. J Biol Chem 2010,
285:5385–5391.
11. Toda N, Ayajiki K, Okamura T: Cerebral blood flow regulation by nitric
oxide in neurological disorders. Can J Physiol Pharmacol 2009, 87:581–594.
12. Scriver CR, Perry TL: Disorders of omega-amino acids in free and peptide-
linked forms. In The Metabolic Basis of Inherited Disease Vol. 1. Edited by
Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill Press; 1989:
pp 755–771.
13. Kotani K, Ueno S, Sano A, Kakimoto Y: Isolation and identification of
methylarginines from bovine brain. J Neurochem 1992, 58:1127–1129.14. Ueno S, Sano A, Kotani K, Kondoh K, Kakimoto Y: Distribution of free
methylarginines in rat tissues and in the bovine brain. J Neurochem 1992,
59:2012–2016.
15. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS,
Vallance P: Identification of two human dimethylarginine
dimethylaminohydrolases with distinct tissue distributions and
homology with microbial arginine deiminases. Biochem J 1999,
343:209–214.
16. Kayrak M, Bacaksiz A, Vatankulu MA, Ayhan SS, Taner A, Unlü A, Yazici M,
Ulgen MS: Association between exaggerated blood pressure response to
exercise and serum asymmetric dimethylarginine levels. Circ J 2010,
74:1135–1141.
17. Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B, Hu B,
Troughton RW, Klein AL, Hazen SL: Differential effects of arginine methylation
on diastolic dysfunction and disease progression in patients with chronic
systolic heart failure. Eur Heart J 2008, 29:2506–2513.
18. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an
endogenous inhibitor of nitric oxide synthesis in chronic renal failure.
Lancet 1992, 339:572–575.
19. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S,
Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A,
Stidwill R, McDonald NQ, Vallance P: Disruption of methylarginine metabolism
impairs vascular homeostasis. Nat Med 2007, 13:198–203.
20. Vogt BA, Vogt LJ, Farber NB: Cingulate cortex and models of disease. In
The Rat Nervous System. 3rd edition. Edited by Paxinos G. U.S.A: Elservier;
2004:pp705–727.
21. Cooper BG, Mizumori SJY: Retrosplenial cortex inactivation selectively
impairs navigation in darkness. Neuro Rep 1999, 10:625–630.
22. Pengas G, Williams G, Cabronero JA, Ash TJ, Hong Y, Garcia DI, Fryer T,
Hodges J, Nestor J: The relationship of topographical memory performance
to regional neurodegeneration in Alzheimer’s disease. Front Aging Neurosci
2012, 4:article 17.
23. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE: Metabolic
reduction in the posterior cingulate cortex in very early Alzheimer's
disease. Ann Neurol 1997, 42:85–94.
24. Villain N, Desgranges B, Viader F, de la Sayette V, MVzenge F, Landeau B,
Baron JC, Eustache FC, Eust G: Relationships between hippocampal
atrophy, white matter disruption, and gray matter hypometabolism in
Alzheimer's disease. J Neurosci 2008, 28:6174–6181.
25. Vann SD, Aggleton JP, Maguire EA: What does the retrosplenial cortex do?
Nat Rev Neurosci 2009, 10(11):792–802.
doi:10.1186/1471-2202-15-53
Cite this article as: Abe et al.: Distribution of D-3-aminoisobutyrate-
pyruvate aminotransferase in the rat brain. BMC Neuroscience 2014 15:53.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
